{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:34:31Z","timestamp":1790087671081,"version":"4.0.1"},"reference-count":23,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.1253\/circj.cj-25-0089","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T18:05:08Z","timestamp":1743098708000},"page":"1256-1265","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia\u3000\u2015 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial) \u2015"],"prefix":"10.1253","volume":"89","author":[{"given":"Shizuya","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihiro","family":"Kiyosue","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yokota","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. <i>Lancet<\/i> 2020; 395: 795\u2013808.","DOI":"10.1016\/S0140-6736(19)32008-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions a systematic review and meta-analysis. <i>JAMA<\/i> 2016; 316: 1289\u20131297.","DOI":"10.1001\/jama.2016.13985"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants. <i>Lancet Diabetes Endocrinol<\/i> 2020; 8: 36\u201349.","DOI":"10.1016\/S2213-8587(19)30388-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: The Hisayama study. <i>Stroke<\/i> 2009; 382: 382\u2013388.","DOI":"10.1161\/STROKEAHA.108.529537"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. <i>J Atheroscler Thromb<\/i> 2024; 31: 641\u2013853.","DOI":"10.5551\/jat.GL2022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet<\/i> 2016; 388: 2532\u20132561.","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ma PT, Gil G, S\u00fcdhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. <i>Proc Natl Acad Sci USA<\/i> 1986; 83: 8370\u20138374.","DOI":"10.1073\/pnas.83.21.8370"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mitani H, Suzuki K, Ako J, Iekushi K, Majewska R, Touzeni S, et al. Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan. <i>J Atheroscler Thromb<\/i> 2023; 30: 1622\u20131634.","DOI":"10.5551\/jat.63940"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. <i>Nat Commun<\/i> 2016; 7: 13457.","DOI":"10.1038\/ncomms13457"},{"key":"10","unstructured":"10. NEXLETOL<sup>\u00ae<\/sup> highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211616s012s013lbl.pdf (accessed January 20, 2025)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. <i>N Engl J Med<\/i> 2023; 388: 1353\u20131364.","DOI":"10.1056\/NEJMoa2215024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamashita S, Fujita H, Yokota D, Morikawa-Isogai Y, Kitamoto R. Efficacy and safety of bempedoic acid for hypercholesterolemia in Japan: A Phase 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding trial. <i>J Atheroscler Thromb<\/i> 2025, doi:10.5551\/jat.65336.","DOI":"10.5551\/jat.65336"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. <i>J Atheroscler Thromb<\/i> 2018; 25: 846\u2013984.","DOI":"10.5551\/jat.GL2017"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). <i>Am J Cardiol<\/i> 2010; 105: 69\u201376.","DOI":"10.1016\/j.amjcard.2009.08.651"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). <i>Am J Cardiol<\/i> 2007; 99: 673\u2013680.","DOI":"10.1016\/j.amjcard.2006.10.022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. <i>Am J Cardiol<\/i> 2013; 112: 1885\u20131895.","DOI":"10.1016\/j.amjcard.2013.08.031"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. <i>J Clin Lipidol<\/i> 2016; 10: 556\u2013567.","DOI":"10.1016\/j.jacl.2015.12.025"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>Eur J Prev Cardiol<\/i> 2020; 27: 593\u2013603.","DOI":"10.1177\/2047487319864671"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. <i>Eur Heart J<\/i> 2013; 34: 3478\u20133490.","DOI":"10.1093\/eurheartj\/eht273"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, et al. ETC 1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. <i>J Lipid Res<\/i> 2013; 54: 2095\u20132108.","DOI":"10.1194\/jlr.M035212"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. <i>Cardiovasc Drugs Ther<\/i> 2021; 35: 853\u2013864.","DOI":"10.1007\/s10557-021-07147-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomised trial. <i>Lancet Diabetes Endocrinol<\/i> 2024; 12: 19\u201328.","DOI":"10.1016\/S2213-8587(23)00316-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. <i>N Engl J Med<\/i> 2019; 380: 1033\u20131042.","DOI":"10.1056\/NEJMoa1806747"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/8\/89_CJ-25-0089\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T03:40:18Z","timestamp":1753501218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/8\/89_CJ-25-0089\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-0089","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"CJ-25-0089"}}